5-HT3 blockade does not attenuate postspinal blood pressure change in cesarean section: A case-control study.
Adult
Anesthesia, Obstetrical
/ methods
Anesthesia, Spinal
/ methods
Apgar Score
Arterial Pressure
/ drug effects
Case-Control Studies
Cesarean Section
/ adverse effects
Female
Heart Rate
/ drug effects
Humans
Infant, Newborn
Ondansetron
/ administration & dosage
Pregnancy
Retrospective Studies
Serotonin 5-HT3 Receptor Antagonists
/ administration & dosage
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
04 Sep 2020
04 Sep 2020
Historique:
entrez:
9
9
2020
pubmed:
10
9
2020
medline:
25
9
2020
Statut:
ppublish
Résumé
Spinal anesthesia (SpA) for elective caesarean section (CS) is often accompanied by clinically relevant arterial hypotension. The Bezold-Jarisch reflex, causing postspinal hypotension, has been shown to be antagonized by serotonin type 3 (5-HT3) blockade. Our aim was to assess if routine prophylactic administration of the 5-HT3 antagonist ondansetron (ODS) attenuates postspinal change in maternal blood pressure.Elective CS under SpA were retrospectively analyzed. Eighty parturients having routinely received 8 mg ODS prior to SpA were compared with 80 patients having not (control group).Mean arterial blood pressure significantly decreased from baseline to the postspinal period (P < .0001) without differences in blood pressure decreases between the 2 groups. This also applied to the heart rate. Overall use of cafedrine/theodrenaline was higher in the ODS group (0.8 (0.4-1.6) mL vs 0.8 (0-1.0) mL in the control group, P = .01). APGAR values showed a presumably clinically irrelevant decrease in control group compared with the ODS group.Our results suggest that routine administration of ODS in a dosage of 8 mg does not effectively attenuate postspinal change in maternal blood pressure during CS in our setting. Given the wide variability of anesthetic techniques, only large prospective and randomized multicenter trials will ultimately serve to elucidate this issue.
Identifiants
pubmed: 32899016
doi: 10.1097/MD.0000000000021864
pii: 00005792-202009040-00028
pmc: PMC7478381
doi:
Substances chimiques
Serotonin 5-HT3 Receptor Antagonists
0
Ondansetron
4AF302ESOS
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e21864Références
Anesth Analg. 2016 Oct;123(4):977-88
pubmed: 27537930
Reg Anesth Pain Med. 2008 Jul-Aug;33(4):332-9
pubmed: 18675744
J Med Assoc Thai. 2006 Sep;89 Suppl 3:S58-64
pubmed: 17718270
Minerva Ginecol. 2010 Dec;62(6):515-24
pubmed: 21079573
Anaesthesia. 2018 Jan;73(1):71-92
pubmed: 29090733
J Med Assoc Thai. 2006 Aug;89(8):1127-32
pubmed: 17048420
Anesthesiology. 2016 Feb;124(2):270-300
pubmed: 26580836
Int J Clin Exp Med. 2014 Dec 15;7(12):5210-6
pubmed: 25664023
Anesth Analg. 1995 Jun;80(6):1158-62
pubmed: 7762845
Acta Anaesthesiol Taiwan. 2004 Sep;42(3):175-8
pubmed: 15551897
Eur J Clin Pharmacol. 2018 Oct;74(10):1201-1214
pubmed: 29858921
Int J Surg Case Rep. 2016;23:74-6
pubmed: 27100952
Anesth Analg. 1998 Aug;87(2):347-54
pubmed: 9706929
Am J Physiol. 1990 Feb;258(2 Pt 2):H466-72
pubmed: 2309912
J Anaesthesiol Clin Pharmacol. 2015 Jul-Sep;31(3):329-32
pubmed: 26330710
Clin Pract. 2015 Feb 17;5(1):668
pubmed: 25918626
J Am Coll Cardiol. 1983 Jan;1(1):90-102
pubmed: 6826948
Front Pharmacol. 2017 Feb 21;8:68
pubmed: 28270765
Can J Anaesth. 2004 Mar;51(3):226-30
pubmed: 15010403
Anesth Analg. 2000 Jun;90(6):1390-5
pubmed: 10825326
Int J Obstet Anesth. 2014 May;23(2):138-43
pubmed: 24631057
J Anesth. 2018 Feb;32(1):90-97
pubmed: 29243058
Int J Obstet Anesth. 2012 Jan;21(1):24-8
pubmed: 22100822
Jpn J Pharmacol. 1995 Dec;69(4):351-6
pubmed: 8786638